Unity Biotechnology to dissolve; Nasdaq delisting effective July 9, 2025

Unity Biotechnology, Inc.

Board approved Plan of Dissolution; stockholder vote required before filing certificate of dissolution.
Nasdaq notified company it no longer has an operating business; stock will be suspended July 9, 2025; company will not appeal.
All eight directors resigned; Craig R. Jalbert appointed sole director, President, and principal executive/financial/accounting officer.
CEO Anirvan Ghosh, CFO Lynne Sullivan, and CLO Alexander Nguyen departed effective June 27.
Company had previously implemented substantial reduction in force and closed its Phase 2b ASPIRE study.

item 3.01item 5.02item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.